it has acquired a royalty interest in worldwide sales of Xenpozyme for US$30-million. The company said additional performance-based milestones of up to US$26.5-million could be paid if sales of the drug outperform expectations.
The company said Xenpozyme is the only product developed and approved for the treatment of non-central nervous system manifestations of acid sphingomyelinase deficiency , also known as Niemann-Pick disease. “Xenpozyme is a product that provides ASMD patients and their families with a disease-modifying therapy where none previously existed. The drug represents a transformational shift in therapies available to patients who suffer from ASMD,” said CEO Behzad Khosrowshahi.
Belgique Dernières Nouvelles, Belgique Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
La source: TorontoStar - 🏆 60. / 55 Lire la suite »